PROPRANOLOL TREATMENT OF INFANTILE HEMANGIOMA: OUR PRELIMINARY RESULTS

Corina Stănciulescu 1,2*, CM Popoiu 1,2, Anca Popoiu 1,2, Șt. Lazea 1,2, A. Lăcătușu 1,3, Patricia Cristodor 1,4, VL David 1,2, Emanuela Verenca1, ES Boia 1,2

Abstract
Infantile hemangiomas (IH) are the most common benign vascular tumors in childhood, affecting 4-5% of Caucasian infants in their first year of life.

We performed a prospective study of 34 cases of IH treated with propranolol from May 2010 to December 2012. Beta blocker treatment was administered in 21 girls and 13 boys aged 2 to 14 months (mean age 5.4 months). All patients were evaluated with electrocardiography and echocardiography prior to start of treatment. Propranolol was administered at a dose of 1mg/kg/day divided in 3 equal parts (day 1) and 2mg/kg/day divided in 3 equal parts (day 2), continuing with this dose throughout the rest of the treatment. The treatment was initiated during a 24-48 hours hospitalization, time during which blood pressure and heart rate were measured every 6 hours. After 24 hours of hospitalization we performed an EKG and measured the blood glucose level. None of our patients developed hypotension, hypoglycemia or bronchospasm.

The results are: very good-70.96%, good-16.12%, partial-6.45%, no response- 6.45%. Three patients were uncooperative and after 1 month to treatment they have not presented to control and stop the treatment.

Keywords: infantile hemangioma, propranolol, treatment, beta blocker

Introduction
What is hemangioma? What is infantile hemangioma? What is congenital hemangioma? The terminology used for vascular lesions has been very confusing until 1982, when Mulliken and Glowacki classified the common cutaneous vascular lesions of childhood into two categories, based on endothelial cell characteristics: hemangiomas and vascular malformations [1,2,3,4].

In 1996, the International Society for the Study of Vascular Anomalies (ISSVA) accepted the classification of vascular anomalies into vascular tumors and vascular malformations, based on clinical, radiological and pathological characteristics [5,6]. Hemangiomas represented the most vascular tumor of infancy and can be divided into two categories: infantile hemangiomas and congenital hemangiomas. IH is the most common benign vascular tumor of infancy, occurring in an estimated 4-5% of Caucasian infants [7,8].

The typical IH is not present at birth, appearing a few days postnatally, it rapidly grows during the first year and regresses slowly by the age of 7 years. One third of IH may be apparent as a stain at birth. They are more common in females (3:1) and premature babies with birth weight of less than 1500 grams. The lesions may be classified by clinical type into superficial, deep and mixed [9]. Medical history should focus on determining whether or not the lesion is present at birth, its growth rate (proportional versus disproportional), and if episodic enlargement occurred at any point [10].

The diagnosis of IH is based on medical history and physical examination. Imaging techniques are sometimes used to evaluate the extent of the lesion, differential diagnosis and follow-up of response to treatment [4].

Two approaches can be adopted in the management of infantile hemangiomas: the expectant “wait and see” attitude or the therapeutic (either medical or surgical) attitude. The methods of treatment include: systemic corticosteroid therapy, intralesional corticosteroids, interferon α, Vincristine, laser therapy, cryotherapy, surgical excision [10].

By a chance, Leaute-Labreze C et al. [11] discovered the propranolol’s effects for infantile hemangioma. They treated for hypertrophic myocardiopathy an infant with a nasal infantile hemangioma with enlarging lesion despite corticoid treatment and observed propranolol’s inhibitory effect on hemangioma proliferation.

Synthesized by James W. Black [12] in the early 1960s, propranolol has been used extensively in children and neonates in pediatric cardiology. The indications for propranolol use have now exceeded the spectrum of cardiology, as the drug has been proven useful in pathologies like migraines, infantile hemangiomas, portal hypertension, post-traumatic stress and cancer [11,13,14,15].

1University of Medicine and Pharmacy “Victor Babeș” Timișoara, România, *PhD Student
2Emergency Children’s Hospital “Louis Țurcanu” Timișoara, România
3Department of Pediatrics No. 2, Timișoara, România
4Dermatology Clinic of Timișoara, România
E-mail: stanciulescucorina@yahoo.com, mcpopoiu@yahoo.com, apopoiu2004@yahoo.com, stefianlazea@yahoo.com, adilacatus@yahoo.com, patricia.cristodor@gmail.com, david.vlad@yahoo.com, emma_ver@yahoo.com, boiaeugen@yahoo.com
<table>
<thead>
<tr>
<th>No</th>
<th>Gender</th>
<th>Localization</th>
<th>Type of IH</th>
<th>Age at onset</th>
<th>Age at end</th>
<th>Duration</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>F</td>
<td>Periorbital</td>
<td>Deep</td>
<td>9 mo</td>
<td>15 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capillary malformation of major labia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No response</td>
</tr>
<tr>
<td>2.</td>
<td>M</td>
<td>Periorbital</td>
<td>Deep</td>
<td>5 mo</td>
<td>13 mo</td>
<td>8 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>3.</td>
<td>M</td>
<td>Face (cheek)</td>
<td>Deep</td>
<td>14 mo</td>
<td>20 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>4.</td>
<td>M</td>
<td>Scalp (occipital) and lower lip</td>
<td>Mixed</td>
<td>5 mo</td>
<td>13 mo</td>
<td>8 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>5.</td>
<td>F</td>
<td>Forearm and scalp</td>
<td>Superficial</td>
<td>6 mo</td>
<td>16 mo</td>
<td>10 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>6.</td>
<td>M</td>
<td>Periorbital</td>
<td>Deep</td>
<td>6 mo</td>
<td>14 mo</td>
<td>8 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>7.</td>
<td>F</td>
<td>Cervical area and forearm</td>
<td>Superficial</td>
<td>6 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Good</td>
</tr>
<tr>
<td>8.</td>
<td>M</td>
<td>Right calf</td>
<td>Superficial</td>
<td>7 mo</td>
<td>15 mo</td>
<td>8 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>9.</td>
<td>F</td>
<td>Face (chin)</td>
<td>Superficial</td>
<td>5 mo</td>
<td>6 mo</td>
<td>1 mo Retract</td>
<td>Uncooperative patient</td>
</tr>
<tr>
<td>10.</td>
<td>F</td>
<td>Forehead</td>
<td>Superficial</td>
<td>5 mo</td>
<td>8 mo</td>
<td>3 mo Retract</td>
<td>No response Surgical excision</td>
</tr>
<tr>
<td>11.</td>
<td>F</td>
<td>Forearm and abdominal wall</td>
<td>Superficial</td>
<td>3 mo</td>
<td>12 mo</td>
<td>9 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>12.</td>
<td>M</td>
<td>Fingers</td>
<td>Superficial</td>
<td>5 mo</td>
<td>11 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>13.</td>
<td>F</td>
<td>Left hand</td>
<td>Superficial</td>
<td>5 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>14.</td>
<td>F</td>
<td>Right breast</td>
<td>Mixed</td>
<td>2 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Good</td>
</tr>
<tr>
<td>15.</td>
<td>F</td>
<td>Left breast and scalp</td>
<td>Superficial</td>
<td>6 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Good</td>
</tr>
<tr>
<td>16.</td>
<td>M</td>
<td>Ear lobe</td>
<td>Superficial</td>
<td>2 mo</td>
<td>8 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>17.</td>
<td>F</td>
<td>Labia major</td>
<td>Superficial</td>
<td>7 mo</td>
<td>8 mo</td>
<td>1 mo Retract</td>
<td>No response Uncooperative patient</td>
</tr>
<tr>
<td>18.</td>
<td>F</td>
<td>Face</td>
<td>Superficial</td>
<td>5 mo</td>
<td>6 mo</td>
<td>1 mo Retract</td>
<td>No response Uncooperative patient</td>
</tr>
<tr>
<td>19.</td>
<td>F</td>
<td>Upper eyelid, thorax, fingers</td>
<td>Superficial</td>
<td>2 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Good</td>
</tr>
<tr>
<td>20.</td>
<td>F</td>
<td>Abdominal wall</td>
<td>Superficial</td>
<td>4 mo</td>
<td>12 mo</td>
<td>8 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>21.</td>
<td>M</td>
<td>Abdominal wall</td>
<td>Superficial</td>
<td>8 mo</td>
<td>16 mo</td>
<td>8 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>22.</td>
<td>M</td>
<td>Shoulder</td>
<td>Superficial</td>
<td>8 mo</td>
<td>9 mo</td>
<td>1 mo Retract</td>
<td>No response Surgical excision</td>
</tr>
<tr>
<td>23.</td>
<td>M</td>
<td>Abdominal wall</td>
<td>Superficial</td>
<td>2 mo</td>
<td>8 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>24.</td>
<td>F</td>
<td>Face</td>
<td>Mixed</td>
<td>5 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>25.</td>
<td>F</td>
<td>Scalp and right calf</td>
<td>Superficial</td>
<td>4 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>26.</td>
<td>M</td>
<td>Scalp and thorax</td>
<td>Superficial</td>
<td>8 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>27.</td>
<td>M</td>
<td>Lower lip</td>
<td>Mixed</td>
<td>14 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>28.</td>
<td>F</td>
<td>Lower eyelid</td>
<td>Superficial</td>
<td>3 mo</td>
<td>9 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>29.</td>
<td>F</td>
<td>Left calf</td>
<td>Superficial</td>
<td>6 mo</td>
<td>12 mo</td>
<td>6 mo</td>
<td>Very good</td>
</tr>
<tr>
<td>30.</td>
<td>F</td>
<td>Thorax</td>
<td>Mixed</td>
<td>2 mo</td>
<td>14 mo</td>
<td>12 mo</td>
<td>Partial</td>
</tr>
<tr>
<td>31.</td>
<td>M</td>
<td>Forehead</td>
<td>Superficial</td>
<td>5 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Partial</td>
</tr>
<tr>
<td>32.</td>
<td>F</td>
<td>Right ankle</td>
<td>Superficial</td>
<td>2 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>33.</td>
<td>M</td>
<td>Scalp</td>
<td>Superficial</td>
<td>2 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Very good</td>
</tr>
<tr>
<td>34.</td>
<td>F</td>
<td>Face and cervical</td>
<td>Mixed</td>
<td>6 mo</td>
<td>-</td>
<td>Ongoing</td>
<td>Good</td>
</tr>
</tbody>
</table>

Table 2. Characteristics of the patients

**Materials and methods**

We present our preliminary data from 34 children with 44 infantile hemangioma treated with oral propranolol, during the May 2010 to December 2012 timeframe. (Table1.)

Informed consent from the parents/guardians of each patient was obtained in all cases. Clinical pictures have been taken before the start of treatment and at each subsequent visit. Inclusion criteria were infants newly diagnosed with IH who had not been previously treated with local or systemic corticosteroids.

Beta blocker treatment was administered to 21 girls and 13 boys aged between 2 months and 14 months (mean age 5.4 months). Treatment was discontinued if the lesion completely disappeared, if parents decided to cease the
medication or if after 1 or 3 month of treatment there was no improvement, and the family was offered surgical treatment.

Prior to administration of the drug, all patients were clinically evaluated by a pediatric cardiologist, then underwent electrocardiography (EKG) and echocardiography.

We have used the Prof. Dr. Cremer therapeutic scheme: propranolol was administrated at a dose of 1mg/kg/day divided in 3 equal parts (day1) and 2mg/kg/day divided in 3 equal parts (day 2), continuing with this dose throughout the rest of the treatment[16,17]. We have initiated the treatment during a hospitalization of 24-48 hours. The blood pressure, blood glucose and the heart rate were carefully monitored every 6 hours. After 24 hours we have remeasured child blood glucose and registered the EKG profile. In all cases, the drug was well tolerated and the treatment was continued at home. Monthly, we have evaluated the clinical and photographic evolution of the hemangioma, and we monitored the heart rate, blood pressure, blood glucose and performed an EKG. A repeat echocardiogram was performed after 2 months of treatment.

During the period of observation, the family was instructed to report any evidence of evolution, and none reported or received other therapies for other medical problems.

Fig. 1. Case 1: A. Before treatment; B. After 5 months; C. After 8 months; D. After 9 months from treatment cessation.

Fig. 2. Case 2: A. Before treatment with Propranolol; B. After 9 months; C. After 12 months.
Fig. 3. Case 3: A. Before treatment; B. After 3 months; C. After 6 months.

Fig. 4. Case 4: A. Before; B. After 8 months; C. After 1 years and 6 month.
The outcome of each lesion was defined by its status at the last recorded patient visit. Outcomes are classified as: 1-very good if the final observation indicates that the lesion has more than 90% disappeared, 2-good if the lesion has more than 70% disappeared, 3-partial if the lesion has less than 50% disappeared, 4-early removing from study by parents.

Results

The distribution of the 44 hemangiomas was as follows: 24 cases on the head and neck (2 forehead, 3 periorbital, 2 upper eyelid, 1 lower eyelid, 2 lower lip, 5 facial, 2 cervical, 1 at ear lobe, and 6 scalp); 8 cases on the trunk (3 thorax, 2 breast and 3 abdominal wall); 11 cases on the extremities, and 1 case in the anogenital region. Lesion type was multifocal in 9 cases.

Three patients left the study after only 1 month of treatment, based on parent’s decision.

The treatment did not affect blood pressure and heart rate. None of the parents reported wheezing, and food intake was regular.

Outcomes are: 22 cases (16 completed treatment)-very good (70.96%), 5 cases (still in treatment)- good (16.12%), and 2 cases –partial response (6.45%).

In two cases (6.45%) after 1 month and 3 months of treatment, the lesions did not respond to propranolol and the surgical excision was performed.

One case present one deep infantile hemangioma of the periorbital area and a capillary malformation of the major labia. After 6 months the treatment with propranolol, the periorbital infantile hemangioma present total regression, but the capillary malformation is unchanged.

Only one patient, with a large facial and cervical infantile hemangioma, received another form of treatment (cryotherapy) before propranolol. No relapses were observed in the 16 cases who completed the treatment.

Case presentation

Case 1: 8 month old boy with a calf IH having a rapid growth over a month. Hemangioma was present in the first week of life as a small red stain. Noteworthy to mention, patient also has dextrocardia. After 8 months of treatment solely a teleangiectasia remained on the spot of the hemangioma. 9 months after treatment cessation, the color of skin became normal (Fig. 1).

Case 2: 3 month old girl with an forearm IH present at 3 week of life in the form of little red stains, and having a rapid growth during the last 2 months prior to treatment initiation. After 12 months of treatment the result was very good (Fig. 2).
Discussion

IH are composed of multiple cell types: a majority of endothelial cells associated with pericytes, dendritic cells, and mast cells. Histological analyses of IH have generated many developmental theories suggesting an embryonic or primitive cell origin and these debates will finally determine the best treatment for children [18].

North reported on the GLUT-1 positive staining of IH, suggesting a relation of hemangioma to placental tissue [19].

Bree speculated that invasive angioblasts, differentiated by a type of placental cells, or embolized placental cells may initiate the vascular tumors. However, the study does not demonstrate that placental trophoblast is the cell of origin for IH [20].

The new theories focus on progenitor cells, derangement of angiogenesis, mutation in the cytokine regulatory pathway, and developmental field defects [21,22].

The etiology and pathogenesis of hemangiomas remains unknown. Most IH regress without therapy, so for small and uncomplicated hemangiomas the “wait and see” approach may suffice [23].

The methods of treatment, when required, includes: systemic corticotherapy, intralungal corticosteroids, cytotoxic drugs (bleomycin, vincristine, cyclophosphamide), systemic pharmacologic treatments (interferon α, vincristine and cyclophosphamide), laser therapy, cryotherapy, surgical excision, radiotherapy [10]. Until recently, the first line therapy for complicated IH was systemic corticosteroids [24-26]. The second and third line treatments are vincristine and interferon α, both of which were however linked to severe neurotoxic side effects [26]. In spite of the belief that systemic corticosteroid treatment of IH is very safe [27,28] numerous complications (aseptic necrosis of the femoral head, diabetes, osteoporosis, adrenal insufficiency, cataracts, glaucoma, infection, gastric irritation, elevated blood pressure, cushingoid like aspect, and hypothalamic-pituitary-adrenal axis suppression) have been described [29-33].

After Léauté-Labrèze observation [11] of propranolol's effects on hemangiomas, numerous reports describing the same effects have appeared [18,34,35,36,37]. The new treatment for severe IH is a noncardioselective beta adrenergic receptor blocker: propranolol [38,39]. The mechanism of action of propranolol on IH remains unknown. Regulators of hemangioma growth and involution are poorly understood. During the growth phase, two major proangiogenic factors are involved: basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF). During the involution phase, apoptosis has been shown [40,41]. Potential explanations for the therapeutic effect of propranolol on IH include vasoconstriction, which is immediately visible as a change in color, associated with a palpable softening of the hemangioma; decreased expression of VEGF and bFGF genes through the down-regulation of the RAF–mitogen-activated protein kinase pathway [42,43] (which explains the progressive improvement of the hemangioma); and the triggering of apoptosis of capillary endothelial cells [43].

The mechanism of action of propranolol on IH is open for research but the results obtained seem encouraging.

Conclusion

For the past 40 years, the use of propranolol has been shown to be safe in children with cardiac disease.

In 70.96% of cases, we observed the fading in color and softening of the hemangioma following the administration of propranolol, with no adverse reactions. We consider that systemic therapy with the nonselective beta-adrenergic receptor antagonist propranolol is an effective treatment for IH, due to its rapid therapeutic effect and good drug tolerability.

We believe that the propranolol will become the first line of treatment for IH, although randomized controlled trials should be developed to compare propranolol and corticosteroid therapy.

Ongoing research is bringing us closer to an understanding of the cause of hemangiomas, which will provide opportunities for personalized therapies.

References


Correspondence to:
Calin Popoiu
Pediatric Surgery and Orthopaedics Clinic
Children’s Emergency Hospital “Louis Turcanu”
Timisoara
tel +40256203373
E-mail: mcpopoiu@yahoo.com